← All trials
NCT04336189
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jun 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Apr 7, 2020
- Last posted
- Apr 9, 2020
- Enrollment
- 2757
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- Makerere UniversityOverall official - principal investigator
- Infectious Disease Institute, Kampala, UgandaCollaborator
- University of California, San FranciscoSponsor investigator
- University of California, San FranciscoOverall official - principal investigator
- National Institutes of Health (NIH)Collaborator
- University of California, San FranciscoStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.